1. Comparison of Outcomes between Brachytherapy and Intensity Modulated Radiotherapy in High Risk Prostate Cancer M. A. Weller, C. A. Reddy, J. Kittel, K. Smith, R. D. Tendulkar, K. L. Stephans, E. A. Klein, K. W. Angermeier, J. Ulchaker, S. Campbell, A. Stephenson, J. P. Ciezki 1. Cleveland Clinic, Cleveland, OH

2. Purpose/Methods To study the outcomes in patients treated for high risk prostate cancer (PCA) with low-dose-rate brachytherapy (BT), in comparison to those treated with dose-escalated intensity modulated radiotherapy (IMRT) in combination with androgen deprivation therapy (ADT) 453 patients with high risk (NCCN criteria) PCA treated between 1997 and 2010 at a single institution: – 295 (65%) patients were treated with BT with or without ADT – 158 (35%) patients were treated with IMRT and ADT

3. Survival Curves and MVAs

4. Conclusions After adjusting for stage, PSA, Gleason Score, and ADT use, there was no difference in bRFS or DMFS between patients treated with brachytherapy compared to those treated with IMRT in combination with ADT On multivariate analysis, Gleason score was the only factor that significantly predicted for distant metastases Further study is warranted to validate this approach